ALSO NOTED: Pfizer's Kindler can't quash mega-deal talk; FDA to review Pegintron;and much more...

> Some Pfizer investors are clamoring again for a big acquisition just days after CEO Jeff Kindler said he wouldn't play Let's Make a Deal. Mega-M&A is just too disruptive, Kindler said at last Wednesday's analyst confab. But a CreditSuisse analyst maintains that "a large scale deal may be the best option" for shoring up the company. Report [1]

> The FDA has delayed an advisory board meeting to review the use of Pegintron for serious skin cancer. Report [2]

> The FDA has approved Spectrum Pharmaceuticals' Levoleucovorin for injection after high-dose methotrexate therapy in patients with osteosarcoma. A supplemental NDA for colorectal cancer is planned for mid-year. Release [3]

> The FDA has approved Auriga Laboratories' Liquadd Oral Solution 5 mg/5 mL for ADHD. Release [4]

> Is it a pre-emptive strike? Late Friday Amgen added new warnings to the embattled anemia drugs Aranesp (Amgen) and Procrit (Johnson & Johnson). Report [5]

> Is Pfizer eyeing Chinese outsourcing? Report [6]

> What does it take to cut a CEO's compensation package by almost 20 percent? Ask David Brennan (photo [7]), head honcho at AstraZeneca. Report [8]

And Finally... Don't drink the water? Prescription drugs are in the water supply of more than two dozen cities, according to an investigation that's sure to catch a lot of attention over the next few days. Report [9]